Insider Selling: Rapid Micro Biosystems (NASDAQ:RPID) Major Shareholder Sells $31,420.34 in Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) major shareholder Longitude Capital Partners Ii, sold 7,739 shares of the firm’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $4.06, for a total value of $31,420.34. Following the completion of the transaction, the insider owned 4,029,245 shares of the company’s stock, valued at approximately $16,358,734.70. This represents a 0.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Longitude Capital Partners Ii, also recently made the following trade(s):

• On Monday, February 2nd, Longitude Capital Partners Ii, sold 27,500 shares of Rapid Micro Biosystems stock. The shares were sold at an average price of $4.25, for a total value of $116,875.00.
• On Friday, January 30th, Longitude Capital Partners Ii, sold 46,000 shares of Rapid Micro Biosystems stock. The stock was sold at an average price of $4.54, for a total transaction of $208,840.00.

Rapid Micro Biosystems Stock Down 5.4%

Shares of NASDAQ RPID opened at $3.68 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 4.23 and a quick ratio of 2.95. The stock has a market capitalization of $163.10 million, a P/E ratio of -3.64 and a beta of 1.38. The firm’s 50 day simple moving average is $3.67 and its two-hundred day simple moving average is $3.40. Rapid Micro Biosystems, Inc. has a one year low of $1.86 and a one year high of $4.94.

Rapid Micro Biosystems (NASDAQ:RPID) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). Rapid Micro Biosystems had a negative return on equity of 73.90% and a negative net margin of 145.11%.The firm had revenue of $7.84 million during the quarter, compared to the consensus estimate of $7.60 million. As a group, analysts expect that Rapid Micro Biosystems, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Rapid Micro Biosystems

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RPID. Hudson Bay Capital Management LP purchased a new position in Rapid Micro Biosystems during the 3rd quarter valued at about $38,000. American Century Companies Inc. lifted its position in Rapid Micro Biosystems by 46.1% during the second quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock valued at $58,000 after acquiring an additional 5,341 shares during the last quarter. XTX Topco Ltd purchased a new position in Rapid Micro Biosystems in the second quarter worth $144,000. Dimensional Fund Advisors LP lifted its holdings in shares of Rapid Micro Biosystems by 37.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company’s stock valued at $186,000 after purchasing an additional 15,255 shares during the last quarter. Finally, Susquehanna International Group LLP grew its stake in Rapid Micro Biosystems by 12.6% during the 3rd quarter. Susquehanna International Group LLP now owns 58,387 shares of the company’s stock worth $195,000 after buying an additional 6,528 shares during the last quarter. Institutional investors own 52.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on RPID. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Thursday, January 22nd. Wall Street Zen cut shares of Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.